Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells

European Journal of Immunology

Volumn 35, Issue 5, 2005, Pages 1371-1380

  Xin, Hong ^a,b   Kikuchi, Toshiaki ^a   Andarini, Sita ^a   Ohkouchi, Shinya ^a   Suzuki, Takuji ^a   Nukiwa, Toshihiro ^a   Huqun, ^c   Hagiwara, Koichi ^c   Honjo, Tasuku ^d   Saijo, Yasuo ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemokine; Fractalkine; Gene therapy; NK cells; T cells

Indexed keywords

ADENOVIRUS VECTOR; FRACTALKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INFILTRATION; CANCER INHIBITION; CANCER TISSUE; CELL ADHESION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DENDRITIC CELL; GENE TRANSFER; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VITRO STUDY; INNATE IMMUNITY; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHEMOKINES, CX3C; FLOW CYTOMETRY; GENE THERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MEMBRANE PROTEINS; MICE; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 21044451263     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200526042     Document Type: Article

References (42)

1. Marincola, F. M., Jaffee, E. M., Hicklin, D. J. and Ferrone, S., Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000. 74: 181-273.
2. Rosenberg, S. A., Progress in human tumor immunology and immunotherapy. Nature 2001. 411: 380-384.
3. Ribas, A., Butterfield, L. H., Glaspy, J. A. and Economou, J. S., Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 2003. 21: 2415-2432.
4. Keilholz, U. and Gore, M. E., Biochemotherapy for advanced melanoma. Semin. Oncol. 2002. 29: 456-461.
5. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E. and Rubin, J. T., A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 1987. 316: 889-897.
6. Fossa, S. D., Martinelli, G., Otto, U., Schneider, G., Wander, H., Oberling, F., Bauer, H.W., Achtnicht, U. and Holdener, E. E., Recombinant interferon alfa-2a with or without vinblastin in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann. Oncol 1992. 3: 301-305.
7. Mier, J. W., Vachino, G., Klempner, M. S., Aronson, F. R., Noring, R., Smith, S., Brandon, E. P., Laird, W. and Atkins, M. B., Inhibition of interleukin-2-induced tumor necrosis factor released by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of inteleukin-2-associated side effects. Blood 1990. 76: 1933-1940.
8. Vogelzang, P. J., Bloom, S. M., Mier, J. W. and Atkins, M. B., Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters. Chest 1992. 101: 746-752.
9. Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004. 4: 11-22.
10. Uchiyama, A., Hoon, D. S., Morisaki, T., Kaneda, Y., Yuzuki, D. H. and Morton, D. L., Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res. 1992. 53: 946-952.
11. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J. 3rd., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D. and Lotze, M. T., Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 1995. 154: 6466-6474.
12. Natsume, A., Mizuno, M., Ryuke, Y. and Yoshida, J., Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther. 1999. 6: 1626-1633.
13. Ono, S. J., Nakamura, T., Miyazaki, D., Ohbayashi, M., Dawson, M. and Toda, M., Chemokines: roles in leukocyte development, trafficking, and effector function. J. Allergy Clin. Immunol. 2003. 111: 1185-1199.
14. Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Glass, M., Burdick, M. D. and Strieter, R. M., Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 1996. 97: 2792-2802.
15. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N. et al., Involvement of chemokine receptors in breast cancer metastasis. Nature 2001. 410: 50-56.
16. Guo, J., Wang, B., Zhang, M., Chen, T., Yu, Y., Regulier, E., Homann, H. E., Qin, Z., Ju, D. W. and Cao, X., Macrophage-derived chemokine transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther. 2002. 9: 793-803.
17. Schroers, R., Davis, C. M., Wanger, H. J. and Chen, S. Y., Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Gene Ther. 2000. 9: 889-897.
18. Xia, D. J., Zhang, W. P., Zheng, S., Wang, J., Pan, J. P., Wang, Q., Zhang, L. H., Hamada, H. and Cao, X., Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther. 2002. 9: 592-601.
19. Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A. and Schall, T. J., A new class of membrane-bound chemokine with a CX3C motif. Nature 1997. 385: 640-644.
20. Rossi, D. and Zlotnik, A., The biology of chemokines and their receptors. Annu. Rev. Immunol. 2000. 18: 217-242.
21. Garton, K. J., Gough, P. J., Blobel, C. P., Murphy, G., Greaves, D. R., Dempsey, P. J. and Raines, E. W., Tumor necrosis factor-a-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 2001. 276: 37993-38001.
22. Hundhausen, C., Misztela, D., Berkhout, T. A., Broadway, N., Saftig, P., Reiss, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V. et al., The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003. 102: 1186-1195.
23. Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T. J. et al., Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997. 91: 521-530.
24. Fong, A. M., Alam, S. M., Imai, T., Haribabu, B. and Patel, D. D., CX3CR1 tyrosine sulfation enhances fractalkine-induced cell adhesion. J. Biol. Chem. 2002. 277: 19418-19423.
25. + cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol. 2002. 168: 6173-6180.
26. Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A. and Littman, D. R., Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 2000. 20: 4106-4114.
27. Sallusto, F., Mackay, C. R. and Lanzavecchia, A., The role of chemokine receptor in primary, effector, and memory immune responses. Annu. Rev. Immunol. 2000. 18: 593-620.
28. Baggiolini, M., Chemokines and leukocyte traffic. Nature 1998. 392: 565-568.
29. Goda, S., Imai, T., Yoshie, O., Yoneda, O., Inoue, H., Nagano, Y., Okazaki, T., Imai, H., Bloom, E. T., Domae, N. et al., CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J. Immunol. 2000. 164: 4313-4320.
30. + monocytes. J. Exp. Med. 2003. 197: 1701-1707.
31. Belardelli, F. and Ferrantini, M., Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002. 23: 201-208.
32. Liu, Y. J., Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001. 106: 259-262.
33. Papadopoulos, E. J., Sassetti, C., Saeki, H., Yamada, N., Kawamura, T., Fitzhugh, D. J., Saraf, M. A., Schall, T., Blauvelt, A., Rosen, S. D. et al., Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is upregulated upon dendritic cell maturation. Eur. J. Immunol. 1999. 29: 2551-2559.
34. Guo, J., Zhang, M., Wang, B., Yuan, Z., Guo, Z., Chen, T., Yu, Y., Qin, Z. and Cao, X., Fractalkine transgene induces T cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int. J. Cancer 2003. 103: 212-220.
35. Guo, J., Chen, T., Wang, B., Zhang, M., An, H., Guo, Z., Yu, Y., Qin, Z. and Cao, X., Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol. Lett 2003. 89: 1-7.
36. Lavergne, E., Combadiere, B., Bonduelle, O., Iga, M., Gao, J. L., Maho, M., Boissonnas, A., Murphy, P. M., Debre, P. and Combadiere, C., Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res. 2003. 63: 7468-7474.
37. Gao, J. Q., Tsuda, Y., Katayama, K., Nakayama, T., Hatanaka, Y., Tani, Y., Mizuguchi, H., Hayakawa, T., Yoshie, O., Tsutsumi, Y. et al., Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res. 2003. 63: 4420-4425.
38. Fraticelli, P., Sironi, M., Bianchi, G., D'Ambrosio, D., Albanesi, C., Stoppacciaro, A., Chieppa, M., Allavena, P., Ruco, L., Girolomoni, G. et al., Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest. 2001. 107: 1173-1181.
39. Cmbien, B., Pomeranz, M., Schmid-Antomarchi, H., Millet, M. A., Breittmayer, V., Rossi, B., and Schmid-Alliana, A., Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. Blood 2001. 97: 2031-2037.
40. Zitvogel, L., Dendritic and natural killer cells cooperate in the control/ switch of innate immunity. J. Exp. Med. 2002. 195: F9-F14
41. Kanazawa, N., Nakamura, T., Tashiro, K., Muramatsu, M., Morita, K., Yoneda, K., Inaba, K., Imamura, S. and Honjo, T., Fractalkine and macrophage-derived chemokine: T cell-attracting chemokines expressed in T cell area dendritic cells. Eur. J. Immunol. 1999. 29: 1925-1932.
42. Carr, M. W., Roth, S. J., Luther, E., Rose, S. S. and Springer, T. A., Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA 1994. 91: 3652-3656.